Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of “Moderate Buy” by Analysts

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $27.40.

OTLK has been the subject of several analyst reports. BTIG Research dropped their target price on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 29th. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. Guggenheim reaffirmed a “buy” rating and set a $12.00 target price on shares of Outlook Therapeutics in a report on Friday, January 17th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Outlook Therapeutics in a research note on Friday, January 17th.

Institutional Investors Weigh In On Outlook Therapeutics

Institutional investors have recently bought and sold shares of the stock. Squarepoint Ops LLC bought a new position in shares of Outlook Therapeutics during the 2nd quarter worth $232,000. AQR Capital Management LLC bought a new position in Outlook Therapeutics in the 2nd quarter worth about $75,000. Christensen King & Associates Investment Services Inc. purchased a new stake in Outlook Therapeutics in the third quarter valued at approximately $55,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Outlook Therapeutics by 55.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock worth $275,000 after acquiring an additional 18,287 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Outlook Therapeutics by 10.0% in the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock worth $1,242,000 after purchasing an additional 21,201 shares in the last quarter. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Trading Down 1.2 %

OTLK opened at $1.67 on Friday. The stock’s fifty day simple moving average is $1.86 and its 200 day simple moving average is $4.63. The stock has a market cap of $53.41 million, a PE ratio of -0.19 and a beta of 0.58. Outlook Therapeutics has a 1-year low of $0.87 and a 1-year high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings data on Friday, December 27th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.06. Equities analysts forecast that Outlook Therapeutics will post -2.25 earnings per share for the current year.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.